Optimized subcutaneous administration of BHV-1300 achieved rapid, deep and sustained lowering of IgG, differentiating Biohaven's (BHVN) new small molecule class of degraders from the monoclonal ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback